Larotrectinib and Ibrutinib: Interaction Details

Brand names
Larotrectinib
VitrakviIVitrakvi
Ibrutinib
Imbruvica
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Larotrectinib

Brand names
  • VitrakviI
  • Vitrakvi

What Happens When You Take Larotrectinib With Ibrutinib

What can happen when they are taken together (rated Major)

Increased sensitive exposure and increase in the incidence or severity of adverse reactions

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Larotrectinib inhibits CYP3A4, so giving it together with a sensitive CYP3A4 substrate is something to avoid. When the combination is unavoidable, the patient should be monitored for heightened adverse reactions to the sensitive substrate.

The concern is that larotrectinib may raise of a sensitive CYP3A4 substrate, and this may make adverse reactions more frequent or more severe. In a study, larotrectinib 100 mg twice daily given with midazolam, a sensitive CYP3A4 substrate, raised midazolam (0 to infinity) and each by 1.7-fold relative to midazolam given alone.1

The Larotrectinib and Ibrutinib Interaction, Explained

Larotrectinib can slow the breakdown of ibrutinib in your body, so ibrutinib levels may rise. Both are cancer medicines. Ibrutinib is cleared mainly by an enzyme called , and larotrectinib can block that enzyme. Higher ibrutinib levels could mean more side effects, such as bleeding or bruising, irregular heartbeat, infections, diarrhea, or low blood counts.

This warning is based on how the drugs are expected to behave, not on a study of these two together. Please keep taking both as prescribed. Talk with your pharmacist or doctor, who can watch you more closely and may adjust your dose to keep you safe.

Mechanism: Larotrectinib is a . Ibrutinib is a sensitive CYP3A4 , so is expected to increase ibrutinib exposure (, ) and the incidence or severity of adverse reactions.

  • Magnitude: Larotrectinib 100 mg BID increased midazolam AUC and Cmax 1.7-fold. No ibrutinib-specific data are cited.
  • Evidence: Theoretical (extrapolated from the probe substrate). Onset unspecified. Severity on file: major.
  • Management: Avoid the combination if possible. If unavoidable, monitor for ibrutinib adverse reactions (e.g., , including atrial fibrillation, infection, cytopenias, diarrhea). Ibrutinib dose may need individualization per the prescriber.

See the 1 reference behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Larotrectinib and Ibrutinib Interact

The likely mechanism

of by larotrectinib

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Larotrectinib and Ibrutinib Interaction

Care teams usually try to avoid this combination. If both medicines are needed, they typically watch more closely for ibrutinib side effects, and the ibrutinib dose may need to be adjusted and individualized by your care team.

  • Keep taking both medicines exactly as prescribed. Do not stop or change either one on your own.
  • Tell your pharmacist and prescriber about all medicines and supplements you take.
  • Report new or worsening bleeding or bruising, palpitations or a racing heartbeat, fever or signs of infection, or ongoing diarrhea.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Larotrectinib or Ibrutinib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: VITRAKVI oral capsules, oral solution, larotrectinib oral capsules, oral solution

    When larotrectinib 100 mg twice daily was given together with midazolam, a sensitive , the (0 to infinity) and of midazolam were each 1.7-fold higher than with midazolam given alone. For 1-hydroxymidazolam, the principal of midazolam, both AUC(0 to infinity) and Cmax rose 1.4-fold.1

Larotrectinib and Ibrutinib: Common Questions

How serious is the Larotrectinib and Ibrutinib interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Larotrectinib and Ibrutinib interaction managed?

Care teams usually try to avoid this combination. If both medicines are needed, they typically watch more closely for ibrutinib side effects, and the ibrutinib dose may need to be adjusted and individualized by your care team. Keep taking both medicines exactly as prescribed. Do not stop or change either one on your own. Tell your pharmacist and prescriber about all medicines and supplements you t… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Larotrectinib and Ibrutinib Interaction

Ask in your own words about taking Larotrectinib and Ibrutinib together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (1)

  1. Product Information: VITRAKVI(R) oral capsules, oral solution, larotrectinib oral capsules, oral solution. Bayer HealthCare Pharmaceuticals Inc (per FDA), Whippany, NJ, 2022. DailyMed
Was this write-up helpful?

Other Serious Interactions of Larotrectinib and Ibrutinib

Also serious with Larotrectinib

Also serious with Ibrutinib

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Larotrectinib

With Ibrutinib

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.